首页> 外文OA文献 >Complex Crystal Structure Determination and in vitro Anti–non–small Cell Lung Cancer Activity of Hsp90N Inhibitor SNX-2112
【2h】

Complex Crystal Structure Determination and in vitro Anti–non–small Cell Lung Cancer Activity of Hsp90N Inhibitor SNX-2112

机译:复合晶体结构测定和体外抗非小细胞肺癌活性HSP90N抑制剂SNX-2112

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

SNX-2112, as a promising anticancer lead compound targeting heat shock protein 90 (Hsp90), absence of complex crystal structure of Hsp90N-SNX-2112 hindered further structural optimization and understanding on molecular interaction mechanism. Herein, a high-resolution complex crystal structure of Hsp90N-SNX-2112 was successfully determined by X-ray diffraction, resolution limit, 2.14 Å, PDB ID 6LTK, and their molecular interaction was analyzed in detail, which suggested that SNX-2112 was well accommodated in the ATP-binding pocket to disable molecular chaperone activity of Hsp90, therefore exhibiting favorable inhibiting activity on three non–small cell lung cancer (NSCLC) cell lines (IC50, 0.50 ± 0.01 μM for A549, 1.14 ± 1.11 μM for H1299, 2.36 ± 0.82 μM for H1975) by inhibited proliferation, induced cell cycle arrest, and aggravated cell apoptosis. SNX-2112 exhibited high affinity and beneficial thermodynamic changes during the binding process with its target Hsp90N confirmed by thermal shift assay (TSA, ΔTm, and −9.51 ± 1.00°C) and isothermal titration calorimetry (Kd, 14.10 ± 1.60 nM). Based on the complex crystal structure and molecular interaction analysis, 32 novel SNX-2112 derivatives were designed, and 25 new ones displayed increased binding force with the target Hsp90N verified by molecular docking evaluation. The results would provide new references and guides for anti-NSCLC new drug development based on the lead compound SNX-2112.
机译:SNX-2112,作为靶向热休克蛋白90(HSP90)的有前途的抗癌铅化合物,没有复合晶体结构的HSP90N-SNX-2112,受到分子相互作用机制的进一步结构优化和理解。这里,通过X射线衍射成功地确定了HSP90N-SNX-2112的高分辨率复合晶体结构,分辨率极限,2.14Å,PDB ID 6LTK,详细分析它们的分子相互作用,这表明SNX-2112是容纳在ATP结合口袋中以禁用HSP90的分子伴侣活性,因此在三个非小细胞肺癌(NSCLC)细胞系上表现出有利的抑制活性(IC50,0.50±0.01μm,H1299的1.14±1.11μm。 H1975的2.36±0.82μm)通过抑制增殖,诱导细胞周期停滞和加重细胞凋亡。 SNX-2112在结合过程中表现出高亲和力和有益的热力学变化,其靶HSP90N通过热移测测定(TSA,ΔTM和-9.51±1.00°C)和等温滴定热量(KD,14.10±1.60nm)。基于复杂的晶体结构和分子相互作用分析,设计了32种新型SNX-2112衍生物,并且25个新的伴随着通过分子对接评价验证的靶HSP90N的结合力。结果将为基于铅化合物SNX-2112提供抗NSCLC新药开发的新参考和指导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号